Laurel Habel to Cyclic Nucleotide Phosphodiesterases, Type 5
This is a "connection" page, showing publications Laurel Habel has written about Cyclic Nucleotide Phosphodiesterases, Type 5.
Connection Strength
0.144
-
Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma. Br J Cancer. 2016 09 27; 115(7):895-900.
Score: 0.144